67 related articles for article (PubMed ID: 38684838)
1. Lower Risks of New-Onset Hepatocellular Carcinoma in Patients With Type 2 Diabetes Mellitus Treated With SGLT2 Inhibitors Versus DPP4 Inhibitors.
Chou OHI; Ning J; Chan RNC; Chung CT; Huang H; Ng K; Dee EC; Lee S; Kaewdech A; Chow AKM; Man NK; Liu T; Jing F; Cheung BMY; Tse G; Zhou J
J Natl Compr Canc Netw; 2024 Jun; 22(2D):. PubMed ID: 38862004
[TBL] [Abstract][Full Text] [Related]
2. Decreased risk of renal cell carcinoma in patients with type 2 diabetes treated with sodium glucose cotransporter-2 inhibitors.
Chiu CH; Wang WY; Chen HY; Liao PL; Jong GP; Yang TY
Cancer Sci; 2024 Jun; 115(6):2059-2066. PubMed ID: 38572526
[TBL] [Abstract][Full Text] [Related]
3. Associations between type 2 diabetes mellitus and chronic liver diseases: evidence from a Mendelian randomization study in Europeans and East Asians.
Zhao Y; Li D; Shi H; Liu W; Qiao J; Wang S; Geng Y; Liu R; Han F; Li J; Li W; Wu F
Front Endocrinol (Lausanne); 2024; 15():1338465. PubMed ID: 38495785
[TBL] [Abstract][Full Text] [Related]
4. Sodium-Glucose Cotransporter-2 Inhibitors and Nephritis Among Patients With Systemic Lupus Erythematosus.
Yen FS; Wang SI; Hsu CC; Hwu CM; Wei JC
JAMA Netw Open; 2024 Jun; 7(6):e2416578. PubMed ID: 38865122
[TBL] [Abstract][Full Text] [Related]
5. Impact of integrative care on cardiovascular disease risk in newly diagnosed type 2 diabetes mellitus patients: A BI-VitalLife Cohort study.
Khunlertkit T; Viangteeravat T; Wangprapa P; Siriwechdaruk S; Ford JM; Pongpirul K
PLoS One; 2024; 19(5):e0302438. PubMed ID: 38809890
[TBL] [Abstract][Full Text] [Related]
6. Potential role of Fibrosis-4 score in hepatocellular carcinoma screening: The Kangbuk Samsung Health Study.
Shin S; Sohn W; Chang Y; Cho Y; Kwon MJ; Wild SH; Byrne CD; Ryu S
Hepatol Res; 2024 Jun; 54(6):551-561. PubMed ID: 38133526
[TBL] [Abstract][Full Text] [Related]
7. Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an open question.
Streba LA; Vere CC; Rogoveanu I; Streba CT
World J Gastroenterol; 2015 Apr; 21(14):4103-10. PubMed ID: 25892859
[TBL] [Abstract][Full Text] [Related]
8. SGLT2i impact on HCC incidence in patients with fatty liver disease and diabetes: a nation-wide cohort study in South Korea.
Cho HJ; Lee E; Kim SS; Cheong JY
Sci Rep; 2024 Apr; 14(1):9761. PubMed ID: 38684838
[TBL] [Abstract][Full Text] [Related]
9. Effect of statin on hepatocellular carcinoma in patients with type 2 diabetes: A nationwide nested case-control study.
Kim G; Jang SY; Han E; Lee YH; Park SY; Nam CM; Kang ES
Int J Cancer; 2017 Feb; 140(4):798-806. PubMed ID: 27861855
[TBL] [Abstract][Full Text] [Related]
10. SGLT2i reduces risk of developing HCC in patients with co-existing type 2 diabetes and hepatitis B infection: A territory-wide cohort study in Hong Kong.
Lee CH; Mak LY; Tang EH; Lui DT; Mak JH; Li L; Wu T; Chan WL; Yuen MF; Lam KS; Wong CKH
Hepatology; 2023 Nov; 78(5):1569-1580. PubMed ID: 37055020
[TBL] [Abstract][Full Text] [Related]
11. Sodium-Glucose Cotransporter-2 Inhibitors Ameliorate Liver Enzyme Abnormalities in Korean Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease.
Euh W; Lim S; Kim JW
Front Endocrinol (Lausanne); 2021; 12():613389. PubMed ID: 34177796
[TBL] [Abstract][Full Text] [Related]
12. Risk of infections in patients with NAFLD and Type 2 Diabetes under treatment with SGLT2 inhibitors and relationship with liver outcomes: A retrospective case-control study.
Bañares J; Manzano-Nuñez R; Prió A; Rivera-Esteban J; Camps-Relats L; Villarejo A; Ruiz-Ortega L; Pons M; Ciudin A; Salcedo MT; Vargas V; Genescà J; Pericàs JM
Front Endocrinol (Lausanne); 2022; 13():945626. PubMed ID: 36093073
[TBL] [Abstract][Full Text] [Related]
13. Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the Block.
Athyros VG; Polyzos SA; Kountouras J; Katsiki N; Anagnostis P; Doumas M; Mantzoros CS
Curr Vasc Pharmacol; 2020; 18(2):172-181. PubMed ID: 30961499
[TBL] [Abstract][Full Text] [Related]
14. Management of Hepatocellular Carcinoma in 2024: The Multidisciplinary Paradigm in an Evolving Treatment Landscape.
Kinsey E; Lee HM
Cancers (Basel); 2024 Feb; 16(3):. PubMed ID: 38339417
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
